Mineralys Therapeutics
Aldosterone synthase inhibitor for hypertension/CKD/OSA
MLYS · Nasdaq · United States
Share price · MLYS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MLYS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026-14.5%
Nothing announced by MLYS that day or the session before.
- 30 Oct 2026-14.4%
- 8 Sep 2026+10.3%
Nothing announced by MLYS that day or the session before.
- 2 Sep 2026+13.6%
Nothing announced by MLYS that day or the session before.
- 3 Jun 2026-13.1%
- 13 May 2026-8.2%
Nothing announced by MLYS that day or the session before.
- 1 May 2026+9.8%
Nothing announced by MLYS that day or the session before.
- 15 Apr 2026+11.3%
Nothing announced by MLYS that day or the session before.
- 31 Mar 2026+15.2%
Nothing announced by MLYS that day or the session before.
- 20 Mar 2026+3.4%
Nothing announced by MLYS that day or the session before.
Share of unusual movement by asset
For each asset, the share of MLYS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Aldosterone synthase (CYP11B2)Small molecule | HypertensionChronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $23M | $101M+ $523M short-term inv. | $57M-$43M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $221M | $138M+ $523M short-term inv. | $241M-$33M operating cash flow | report ↗ |
| 2026-Q1 | — | $24M | $113M+ $533M short-term inv. | $39M-$39M operating cash flow | report ↗ |
| 2025-Q3 | — | $31M | $218M+ $376M short-term inv. | $37M-$29M operating cash flow | report ↗ |
| 2025-Q2 | — | $38M | $102M+ $223M short-term inv. | $43M-$30M operating cash flow | report ↗ |
| 2025-Q1 | — | $38M | $165M+ $178M short-term inv. | $42M-$45M operating cash flow | report ↗ |
| 2024-Q3 | — | $54M | $97M+ $166M short-term inv. | $56M-$50M operating cash flow | report ↗ |
| 2024-Q2 | — | $39M | $68M+ $243M short-term inv. | $41M-$30M operating cash flow | report ↗ |
| 2024-Q1 | — | $31M | $90M+ $248M short-term inv. | $32M-$19M operating cash flow | report ↗ |
| 2023-Q3 | — | $23M | $86M+ $167M short-term inv. | $23M-$19M operating cash flow | report ↗ |
| 2023-Q2 | — | $12M | $101M+ $160M short-term inv. | $12M-$20M operating cash flow | report ↗ |
| 2023-Q1 | — | $12M | $138M+ $132M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2022-Q3 | — | $6.1M | $49M | $6.7M-$7.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.6M | $128M | $6.5M-$5.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $6.8M | $16M | $7.6M-$6.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $132M | $173M+ $484M short-term inv. | $39M-$142M operating cash flow | report ↗ |
Mineralys Therapeutics reported full-year 2025 financial results with revenue not disclosed. R&D spend was $132.01M, down 21.7% YoY. Cash and equivalents were $172.92M, while total cash, cash equivalents and investments were $656.6M as of December 31, 2025. The company reported a net loss of $154.65M for the year and a fourth-quarter net loss of $32.2M.
Management stated that current cash, cash equivalents and investments are expected to fund planned clinical trials, regulatory activities, and corporate operations into 2028. The FDA accepted the NDA for lorundrostat in hypertension, with a PDUFA target date of December 22, 2026. Topline data from the Explore-OSA Phase 2 trial showed no clinically meaningful difference from placebo on the primary AHI endpoint after four weeks, though blood pressure reductions were observed; the Transform-HTN open-label extension trial is ongoing.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $169M | $114M+ $84M short-term inv. | $44M-$166M operating cash flow | report ↗ |
| 2023-FY | — | $70M | $49M+ $187M short-term inv. | $18M-$81M operating cash flow | report ↗ |
| 2022-FY | — | $26M | $88M+ $22M short-term inv. | $7.5M-$29M operating cash flow | report ↗ |
| 2021-FY | — | — | $11M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($8.8M), 57 sales ($27.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-19 | COATS LONNEL · director | Award / grant | 12,400 | — | — | Form 4 |
| 2026-10-19 | Peterson Kristine · director | Award / grant | 12,400 | — | — | Form 4 |
| 2026-10-19 | COATS LONNEL · director | Award / grant (derivative) | 16,600 | — | — | Form 4 |
| 2026-10-19 | Peterson Kristine · director | Award / grant (derivative) | 16,600 | — | — | Form 4 |
| 2026-09-30 | Congleton Jon · director, Chief Executive Officer | Open-market sale | 75,000 | $25.46 | $1.9M | Form 4 |
| 2026-09-22 | Slingsby Brian Taylor · director | Open-market sale | 104,320 | $28.81 | $3.0M | Form 4 |
| 2026-09-21 | Warren Eric · Chief Commercial Officer | Option exercise | 7,438 | $13.24 | $98K | Form 4 |
| 2026-09-21 | Warren Eric · Chief Commercial Officer | Open-market sale | 7,438 | $28.12 | $209K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 213 reporting institutions held 90.9M shares ($2.4B, 110.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Catalys Pacific, LLC | 7,903,838 | $214.1M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 7,692,750 | $208.4M |
| 3 | SAMSARA BIOCAPITAL, LLC | 5,871,018 | $159.0M |
| 4 | FMR LLC | 4,861,104 | $131.7M |
| 5 | BlackRock, Inc. | 4,481,582 | $121.4M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 3,359,068 | $91.0M |
| 7 | STATE STREET CORP | 2,935,940 | $79.5M |
| 8 | Caligan Partners LP | 2,772,654 | $75.1M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2,454,363 | $66.5M |
| 10 | Laurion Capital Management LP | 2,232,040 | $60.5M |
| 11 | ORBIMED ADVISORS LLC | 2,052,900 | $55.6M |
| 12 | Point72 Asset Management, L.P. | 1,911,433 | $51.8M |
| 13 | FRANKLIN RESOURCES INC | 1,784,662 | $48.3M |
| 14 | ANDERA PARTNERS | 1,591,917 | $43.1M |
| 15 | SR One Capital Management, LP | 1,563,966 | $42.4M |